Liposomal Grb-2: Phase I data

Bio-Path disclosed in its 2Q15 earnings data from 21 evaluable patients from the monotherapy portion of a dose-escalation Phase I trial showing that IV liposomal Grb-2 was well tolerated with no DLTs ...